Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27185413 | 0.88 | TSHR (0.47) | TSHRNUDT1KDM5AKDM5BTP53 | |
| SCHEMBL29837473 | 0.82 | TSHR (0.60) | TSHRNUDT1KDM5AKDM5BTP53 | |
| SCHEMBL3515887 | 0.82 | TSHR (0.60) | TSHRNUDT1KDM5AKDM5BTP53 | |
| SCHEMBL277304 | 0.80 | TSHR (0.53) | TSHRNUDT1KDM5AKDM5BTP53 | |
| SCHEMBL13758656 | 0.79 | TSHR (0.52) | TSHRNUDT1KDM5AKDM5BTP53 | |
| SCHEMBL12447815 | 0.79 | TSHR (0.52) | TSHRNUDT1KDM5AKDM5BTP53 | |
| SCHEMBL2568123 | 0.79 | CA12 (0.56) | TSHRNUDT1KDM5AKDM5BTP53 | |
| Bromide SCHEMBL25305290 | 0.78 | SRC (0.40) | TSHRNUDT1KDM5AKDM5BTP53 | |
| SCHEMBL1841640 | 0.78 | ALDH1A1 (0.68) | TSHRNUDT1TP53CASP1CDC7 | |
| SCHEMBL1213901 | 0.78 | CASP1 (0.52) | TSHRNUDT1KDM5AKDM5BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006317-B1 | 5-substituted aminopyrimido [6′,1′:2,3] imidazo [4,5-c] [2,6] naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-06-11 | — | — | US | disclosed |
| US-11999735-B1 | 5-substituted aminopyrimido [6′,1′:2,3] imidazo [4,5-c] [2,6] naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-06-04 | — | — | US | disclosed |
| US-11964975-B1 | 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][2,6]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006317-B1 | 5-substituted aminopyrimido [6′,1′:2,3] imidazo [4,5-c] [2,6] naphthyridine compounds as CK2 inhibitors | CSNK2A2, CSNK2A3, CSNK2A1 | TSHR 3643/4885NUDT1 3501/4885KDM5A 2148/4885 |
| US-11999735-B1 | 5-substituted aminopyrimido [6′,1′:2,3] imidazo [4,5-c] [2,6] naphthyridine compounds as CK2 inhibitors | CSNK2A2, CSNK2A3, CSNK2A1 | TSHR 3643/4885NUDT1 3501/4885KDM5A 2148/4885 |
| US-11964975-B1 | 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][2,6]naphthyridine compounds as CK2 inhibitors | CSNK2A2, CSNK2A3, CSNK2A1 | TSHR 3643/4885NUDT1 3501/4885KDM5A 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.